Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 21 to 30 of 38

TitleReference numberPublishedLast updated
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)TA603
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesTA171
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomibTA586
Lenalidomide plus dexamethasone for previously untreated multiple myelomaTA587
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Myeloma: diagnosis and managementNG35

Results per page

  1. 10
  2. 25
  3. 50
  4. All